Project Grant R01NR022356
Award Date 9/1/26
Completion Date 6/30/31
Dollars Obligated $790K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Wilmington, DE 19803, USA
Similar Awards
- The National Institute of General Medical Sciences awarded The Nemours Foundation $1.14 million on August 15, 2026, under the Biomedical Research and Research Training program (CFDA 93.859) to support the Delaware Comprehensive Sickle Cell Research Center (DE SCD COBRE) in Phase 3 funding. The award funds continued operation of a biomedical research center focused on sickle cell disease care and research development. The center recruits and develops sickle cell researchers across multiple...
- The National Heart, Lung, and Blood Institute awarded Cincinnati Children's Hospital Medical Center $830,260 on July 16, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to implement shared decision-making for pediatric sickle cell disease treatment selection. The project, titled "Implementation of Shared Decision-Making for Sickle Cell Disease (IMPLEMENT-SDM Study)," develops and disseminates a shared decision-making toolkit designed to integrate medical evidence...
- The Defense Health Agency (DHA) awarded The Nemours Foundation's Nemours Biomedical Research - Delaware Division a project grant of $548,659 under the Military Medical Research and Development program (CFDA 12.420) beginning September 1, 2025, with a completion date of August 31, 2028. The award funds research focused on "Characterization of Plexiform Neurofibroma Treatment Susceptibility and Response Through Multidimensional Circulating Biomarkers." This three-year initiative will...
- The National Institutes of Health Office of the Director awarded The Nemours Foundation $1,074,636 on September 15, 2025, under the Trans-NIH Research Support program (CFDA 93.310) for research into precision neurostimulation to restore cognitive function across multiple neurological disorders. The funded research combines in-vivo and in-silico approaches to identify and correct disrupted hippocampal activity patterns shared across disease groups. The study uses six animal models of three common...
- The National Heart, Lung, and Blood Institute awarded $1.834 million to St. Jude Children's Research Hospital Inc. on July 5, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to test senescence-targeting therapies for improving hematopoietic stem cell function and mobilization in sickle cell disease. The research addresses pathologic bone marrow stress in sickle cell disease patients, which damages and depletes hematopoietic stem and progenitor cells and selects for...
- The National Heart, Lung, and Blood Institute awarded Rutgers The State University of New Jersey, School of Nursing, $117,750 on May 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct proteomic profiling and neurocognitive assessment to uncover stroke mechanisms in adults with sickle cell disease. The study quantifies neurodegeneration-associated and mitochondrial proteins in a cohort of 90 sex- and age-matched adults comprising 30 healthy controls, 30...
- The National Heart, Lung, and Blood Institute awarded Duke University $238,516 on August 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct admixture mapping of genetic modifiers in sickle cell disease. The research leverages the National Heart, Lung, and Blood Institute's TOPMed program, which includes multiple cross-sectional adult sickle cell disease cohorts totaling more than 4,000 participants with whole genome sequencing data and extensive clinical...
- The National Institute of Neurological Disorders and Stroke awarded the University of Texas at Arlington $2,083,992 on September 18, 2025, to conduct longitudinal collection and computational modeling of health data in Black adolescents and young adults with sickle cell disease, with an ultimate completion date of August 31, 2030. The project, titled "Modeling Inter-Individual Differences to Address Pain of Sickle Cell Disease (MIDAS)," is supported under the Drug Use and Addiction...
- The National Institute of Neurological Disorders and Stroke awarded Duke University $3.119 million on September 18, 2025, under the Drug Use and Addiction Research Programs (CFDA 93.279) to develop and validate computational and clinical tools for understanding pain variability in sickle cell disease. The funded work constitutes a prospective cohort study enrolling 1,250 individuals aged 15 years and older living with sickle cell disease in the United States. Over three years, the research...
- The National Institute of Nursing Research awarded University of Massachusetts Medical School $7,345,938 on April 16, 2026, under the Nursing Research program (CFDA 93.361) to conduct a multi-state longitudinal study examining the effectiveness of school-based health centers to improve pediatric asthma care and advance health equity. The study will compare asthma outcomes and guideline-based care delivery in school-based health centers against traditional community health centers, focusing on...